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SUMMARY
The tumor suppressor p53 is a transcription factor that responds to cellular stresses by initiating cell
cycle arrest or apoptosis. One transcriptional target of p53 is Mdm2, an E3 ubiquitin ligase that inter-
acts with p53 to promote its proteasomal degradation in a negative feedback regulatory loop. Here
we show that the wild-type p53-induced phosphatase 1 (Wip1), or PPM1D, downregulates p53
protein levels by stabilizing Mdm2 and facilitating its access to p53. Wip1 interacts with and dephos-
phorylates Mdm2 at serine 395, a site phosphorylated by the ATM kinase. Dephosphorylated Mdm2
has increased stability and affinity for p53, facilitating p53 ubiquitination and degradation. Thus,Wip1
acts as a gatekeeper in the Mdm2-p53 regulatory loop by stabilizing Mdm2 and promoting Mdm2-
mediated proteolysis of p53.INTRODUCTION
The tumor suppressor p53 is a transcription factor that re-
sponds to an array of cellular stresses by initiating cell cy-
cle arrest, DNA repair, or apoptosis (Harris and Levine,
2005). These antiproliferative p53 activities prevent a dam-
aged cell from dividing before completion of repair and
potentially becoming cancerous (Lane, 2005). The impor-
tance of p53 in maintaining genomic stability is illustrated
by the fact that more than half of all human cancers lose
p53 function through mutation or deletion of the p53
gene (Martin et al., 2002). After DNA damage, p53 un-
dergoes multiple posttranslational modifications that in-
crease p53 stability and activate it as a potent transcrip-
tion factor (Appella and Anderson, 2001; Bode and
Dong, 2004; Lavin and Gueven, 2006). Activated p53 al-
ters gene transcription patterns that result in engagement342 Cancer Cell 12, 342–354, October 2007 ª2007 Elsevier Inc.of DNA damage response and antiproliferative pathways
that promote DNA repair and prevent cell cycle progres-
sion (Harris and Levine, 2005; Vogelstein et al., 2000).
One transcriptional target of p53 is the Mdm2 gene,
which encodes anE3ubiquitin ligase (Bond et al., 2005;Mi-
chael and Oren, 2003). Mdm2 interacts with p53 andmedi-
ates its ubiquitination, resulting in p53 proteasomal degra-
dation (Michael and Oren, 2003). Thus, Mdm2 is activated
by p53 and in turn destabilizes it as part of an oscillating
negative feedback regulatory loop (Bond et al., 2005).
Given the ability of Mdm2 to suppress p53, it is not surpris-
ing that it is an important oncogene in its own right. A sig-
nificant number of human cancers exhibit Mdm2 gene
amplification and/or overexpression (Momand et al., 1998).
The p53 gene is rarely mutated in these cancers, suggest-
ing thatMdm2 is primarily oncogenic as a result of its ability
to suppress p53 activity (Momand et al., 1998).SIGNIFICANCE
The p53 tumor suppressor is mutated or lost in roughly half of all human cancers. In some human cancers where
p53 remains structurally intact, p53 loss of function can be mediated by amplification and overexpression of the
Mdm2 gene. Mdm2 is a p53-transactivated E3 ubiquitin ligase that promotes p53 degradation in a negative feed-
back regulatory loop. Here we show that Wip1 acts as a molecular gatekeeper in the Mdm2-p53 autoregulatory
loop by downregulating p53 via stabilization of Mdm2. This inhibition of p53 by Wip1 is consistent with observa-
tions that theWip1 gene is amplified and overexpressed in several human tumor types and is oncogenic in rodent
fibroblast transformation assays, providing a molecular mechanism for Wip1 oncogenicity.
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Regulation of the p53-Mdm2 Regulatory Loop by Wip1One aspect of the p53-Mdm2 autoregulatory loop is
that, immediately following DNA damage, both p53 and
Mdm2 are phosphorylated by ATM (ataxia telangiectasia
mutated) and other kinases in a manner that prevents
Mdm2 from interacting with p53, ensuring p53 stabiliza-
tion (Canman et al., 1998; Maya et al., 2001; Tibbetts
et al., 1999). DNA damage-activated ATM and ATR (ataxia
telangiectasia and Rad-3-related) directly phosphorylate
p53 at serine 15 and indirectly at serine 20 via activation
of the Chk1 and Chk2 kinases (Canman et al., 1998; Che-
hab et al., 2000; Hirao et al., 2000; Tibbetts et al., 1999).
ATM also phosphorylates serine 395 on Mdm2 (Maya
et al., 2001). These phosphorylations of p53 and Mdm2
by ATM/ATR inhibit p53-Mdm2 interaction and are associ-
ated with increased ubiquitination and proteolytic degra-
dation of Mdm2, and increased stability of p53 (Bode
and Dong, 2004; Chehab et al., 2000; Maya et al., 2001).
Phosphorylation and stabilization of p53 are also associ-
ated with increased transcriptional activity and engage-
ment of the p53-associated gene expression programs
that facilitate cell cycle arrest and DNA repair (or in
some cases, apoptosis) (Appella and Anderson, 2001;
Bode and Dong, 2004).
Following completion of damage repair, there must be
mechanisms to restore the cell to a prestress homeostatic
state. A key component of this homeostatic restoration
must be a program to reduce p53 activity and levels.
This is likely to be achieved in part by phosphatases that
dephosphorylate p53 and Mdm2 to allow Mdm2-p53 in-
teraction and p53 degradation. Previously, we have
shown that the wild-type p53-induced phosphatase 1
(Wip1) can dephosphorylate p53 at serine 15, a site adja-
cent to the Mdm2 interaction domain on p53 (Fujimoto
et al., 2006; Lu et al., 2005). Moreover, Wip1 can dephos-
phorylate and inactivate p53 targeting kinases ATM,
Chk1, and Chk2 (Fujimoto et al., 2006; Lu et al., 2005;
Oliva-Trastoy et al., 2006; Shreeram et al., 2006; Yoda
et al., 2006), which phosphorylate p53 at serine 15
(ATM) and serine 20 (Chk1/2) adjacent to or within the
Mdm2 interaction site on p53 (Chehab et al., 2000; Hirao
et al., 2000; Yu et al., 2002). We have also shown that
Wip1 dephosphorylation of p53 and Chk1 are correlated
with abrogation of cell cycle checkpoints (Lu et al., 2005).
Wip1 is a serine/threonine phosphatase of the type 2C
protein phosphatase family (PP2C) (Fiscella et al., 1997).
The type 2C phosphatases are conserved from yeast to
humans and are frequently associated with regulation of
cellular stress responses (Choi et al., 2000; Fiscella
et al., 1997). Wip1 has the typical properties of a type 2C
phosphatase in that it is magnesium dependent and in-
sensitive to the phosphatase inhibitor okadaic acid (Fis-
cella et al., 1997; Mumby and Walter, 1993). Evidence is
accumulating that Wip1 is a human oncogene. Wip1 co-
operates with other oncogenes to transform rodent em-
bryonic fibroblasts (Bulavin et al., 2002; Nannenga et al.,
2006). TheWip1 gene is amplified in several human cancer
types (Bulavin et al., 2002; Hirasawa et al., 2003; Li et al.,
2002; Mendrzyk et al., 2005; Saito-Ohara et al., 2003). In
breast cancers with amplified and overexpressed Wip1,Cthe p53 locus is rarely mutated (Bulavin et al., 2002), sug-
gesting thatWip1 amplification inhibits p53 activity and re-
duces selection for p53 mutations during tumor progres-
sion. Recently, it has been demonstrated that Wip1
overexpression in the mammary gland accelerates mam-
mary tumorigenesis in the context of ErbB2 overexpres-
sion (Demidov et al., 2007). Interestingly, reduction of
Wip1 dosage suppresses transformation in rodent fibro-
blasts (Bulavin et al., 2004). Moreover,Wip1 null mice dis-
play a dramatic reduction in spontaneous and oncogene-
induced tumors compared to their wild-type counterparts
(Bulavin et al., 2004; Nannenga et al., 2006). Wip1 inacti-
vation was correlated with activation of p16INK4A and
p53 (Bulavin et al., 2004). Thus, Wip1 is likely to be a
bona fide oncogene, at least in part through its capacity
to suppress p53 activity.
To determine more mechanistically how Wip1 sup-
presses p53, we show here that Wip1, also known as
PPM1D, stabilizes Mdm2 and facilitates its access to
p53. Wip1 dephosphorylates Mdm2 at serine 395, a site
that is phosphorylated by the ATM damage response ki-
nase (Maya et al., 2001). Wip1 dephosphorylation of
Mdm2 inhibits Mdm2 autoubiquitination and results in its
stabilization. In turn, dephosphorylated Mdm2 has in-
creased affinity for p53, and p53 ubiquitination and degra-
dation are increased. Thus, Wip1 acts as a molecular
gatekeeper in the Mdm2-p53 autoregulatory loop by sta-
bilizing Mdm2 and facilitating Mdm2-mediated proteolytic
degradation of p53. This inhibition of p53 by Wip1 may
have clinical implications given the potential therapeutic
uses of compounds that interfere with Wip1 suppression
of p53 activity (Belova et al., 2005; Yamaguchi et al., 2006).
RESULTS
Absence of Wip1 Enhances p53 Transcriptional
Regulatory Functions Following Ionizing Radiation
To further examine how p53 is regulated by Wip1, we as-
sessed the steady-state levels of p53 in humanU2OS cells
expressing wild-type p53 after DNA damage induced by
ionizing radiation (IR). Levels of p53 increased within 2 hr
and further increased up to 6 hr after radiation in control
cells (Figure 1A). Overexpression of Wip1 in U2OS cells
via transfection of a Wip1 expression construct reduced
p53 levels compared to controls. In contrast, inhibiting
Wip1 by transfection of two distinct Wip1 small interfering
RNAs (siRNAs) resulted in higher levels of p53 compared
to that in control cells (Figure 1A). To assess the effects
of Wip1 on p53 transcriptional activity, we transfected
a p53 responsive p21 promoter-luciferase construct along
with either a Wip1 expression construct, Wip1 siRNA, or
an empty vector into U2OS cells and monitored luciferase
activity at varying time points before and after IR treat-
ment. p53 transactivation activity was significantly in-
creased in irradiated U2OS cells transfected with Wip1
siRNA and significantly decreased in cells transfected
with theWip1 construct compared to control vector-trans-
fected cells (Figure 1B). We also examined IR-induced
p53 and p21 protein levels in Wip1+/+ and Wip1/ancer Cell 12, 342–354, October 2007 ª2007 Elsevier Inc. 343
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Regulation of the p53-Mdm2 Regulatory Loop by Wip1Figure 1. Wip1 Inhibits p53 Levels and Transcription Activity
(A) Steady-state levels of p53 are inhibited by Wip1. Wild-type p53-expressing human U2OS cells were transfected with control scrambled siRNA,
wild-typeWip1 expression vector DNA, or Wip1 siRNAs. Twenty-four hours after transfection, cells were irradiated with 5 Gy IR, harvested at various
time points, and immunoblotted as previously described (Lu et al., 2005). The graph was generated by normalizing p53 levels to b-actin levels on the
western blots using quantitation with a GE Storm 860 fluorescence imager.
(B) The transcriptional activity of p53 is suppressed by Wip1. U2OS cells were transfected with control DNA, wild-type Wip1 expression vector DNA,
orWip1 siRNA-1 together with a p21 promoter-luciferase expression vector and Renilla luciferase control vector DNA. Cells were treated with 5Gy IR,
harvested at indicated time points, lysed, and assayed for luciferase activity. Error bars correspond to standard deviation of the mean.
(C) Absence of Wip1 enhances the abundance and activity of p53 and suppresses Mdm2 protein levels in irradiated MEFs. Primary Wip1+/+ and
Wip1/MEFs were harvested from littermate embryos as previously described (Choi et al., 2002). These cells were treated with 5 Gy IR, harvested,
and immunoblotted as indicated.
(D) p53 target genes have enhanced induction or suppression in response to DNA damage in the absence of Wip1.Wip1+/+ andWip1/MEFs were
mock treated or treated with 5 Gy IR. mRNA from each set of cells harvested 4 hr postirradiation was used for gene expression microarray analysis of
p53 target genes using the Affymetrix Mouse Genome 430 2.0 Chips. Green on the heat map indicates a reduction of mRNA level, while red indicates
an increase. Color intensities correspond to relative signal levels on a logarithmic scale.344 Cancer Cell 12, 342–354, October 2007 ª2007 Elsevier Inc.
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Regulation of the p53-Mdm2 Regulatory Loop by Wip1Figure 2. Wip1 Suppresses p53 Accumulation and Promotes Ubiquitination of p53
(A) Wip1 suppresses p53 accumulation regardless of p53 phosphorylation status. Saos-2 cells were transfected with control DNA, wild-typeWip1, or
phosphatase-dead (PD)Wip1 (D314A) expression vectors, or Wip1 siRNA-1, together with vector DNA expressing phosphorylation site-deficient mu-
tant p53 (Crook et al., 1994). Transfected cells were treated with IR, harvested, and immunoblotted with p53 or b-actin (loading control) antibody.
(B) Wip1 promotes ubiquitination of p53. p53 null Saos-2 cells were transfected with control scrambled siRNA, Wip1 expression vector DNA, or Wip1
siRNAs, together with the same amount of p53 expression vector DNA. Twenty-four hours after transfection, cells were treated with or without 5 Gy IR
and protease inhibitors MG132 and MG102, and harvested 6 hr later. Cell lysates were immunoprecipitated with p53 antibody and immunoblotted
with anti-ubiquitin antibody (left panel) or anti-Mdm2 (4B2 and 2A9, Calbiochem) antibody (right panel).littermate mouse embryonic fibroblasts (MEFs). Wip1/
MEFs exhibited higher levels of p53 and its transcriptional
target p21 following IR treatment (Figure 1C), confirming
that Wip1 has a suppressive effect on p53 protein levels
and transactivation activity. In contrast, despite being
a p53 transcriptional target, Mdm2 protein levels were ac-
tually decreased in irradiated Wip1/ MEFs, suggesting
that Wip1 protein may stabilize Mdm2 protein levels. As-
sessment of other known p53 targets by gene expression
array analysis in irradiated and nonirradiatedWip1+/+ and
Wip1/ MEFs showed a greater p53 transactivation on
a number of p53 transactivation targets in Wip1/
MEFs compared toWip1+/+ MEFs (Figure 1D). In addition,
targets of p53 transcriptional repression (e.g., Bcl-2) were
more robustly repressed in Wip1/ MEFs.
Wip1 Destabilization of p53 Is Associated
with Increased p53 Ubiquitination
Wip1 directly dephosphorylates p53 at Ser15 (Lu et al.,
2005); Wip1 may also indirectly reduce phosphorylation
of p53 at Ser20, Ser33, and Ser46 through inactivation
of Chk1, Chk2, and p38 MAP kinase (Fujimoto et al.,
2006; Lu et al., 2005; Oliva-Trastoy et al., 2006; Takekawa
et al., 2000; Yoda et al., 2006). To determine whether sup-
pression of p53 by Wip1 is dependent on p53 phosphory-
lation status, we used a phosphorylation site-deficient
mutant of p53. This mutant p53 had all N-terminal
(S6, S9, S15, T18, S20, S33, and S37) and C-terminal
(S315, S371, S376, S378, and S392) phosphorylation sitesCamutated from serine/threonine to alanine (Crook et al.,
1994). Wip1 retained its ability to inhibit the levels of mu-
tant p53 in p53 null Saos-2 cells both before and after
IR, suggesting that Wip1 must regulate p53 stabilization
in additional ways (Figure 2A). To determine how Wip1 in-
fluences p53 protein levels, we examined p53 ubiquitina-
tion in the presence of increased or decreased Wip1 dos-
age before and after IR treatment. Overexpressed Wip1
resulted in increased p53 ubiquitination, while reduction
of Wip1 via Wip1 siRNA suppressed p53 ubiquitination
in both IR-treated and untreated cells (Figure 2B).
Wip1 Interacts with Mdm2 and Dephosphorylates
It at Serine 395
p53 protein levels are strongly regulated by Mdm2 (Mi-
chael and Oren, 2003). Interestingly, irradiated Wip1/
MEFs exhibited higher p53 protein levels and lower
Mdm2 protein levels than irradiated Wip1+/+ MEFs
(Figure 1C). This suggested that Wip1 may play an impor-
tant role in the p53-Mdm2 autoregulatory loop. The effects
of Wip1 on MDM2 activities are likely to be direct, as we
showed that endogenous Wip1 binds to endogenous
Mdm2 in U2OS cells as measured by reciprocal immuno-
precipitation western blot analyses using Wip1 and Mdm2
antibodies (Figure 3A). If U2OS cells are transfected with
Wip1 siRNA, the Mdm2-Wip1 interaction is lost due to
the absence of Wip1, as expected (Figure 3B). To deter-
mine whether Wip1 dephosphorylates Mdm2, we per-
formed in vitro phosphatase assays by incubating purifiedncer Cell 12, 342–354, October 2007 ª2007 Elsevier Inc. 345
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Regulation of the p53-Mdm2 Regulatory Loop by Wip1Figure 3. Wip1 Interacts with and Dephosphorylates Mdm2
(A) Endogenous Wip1 interacts with endogenous Mdm2. U2OS cells were lysed and immunoprecipitated with Mdm2 (Calbiochem, cat. no. OP144
and OP145) or Wip1 (Trevigen, Cat. no. 2380-MC-100) antibody and immunoblotted with Wip1 or Mdm2 antibody as indicated.
(B) U2OS cells were transfected with control scrambled siRNA or Wip1 siRNA-1, lysed and immunoprecipitated with the above Mdm2 or Wip1 an-
tibody, and immunoblotted with Wip1 or Mdm2 antibody as indicated. Whole-cell lysates (WCL) were also immunoblotted as indicated.
(C) Wip1 dephosphorylates Mdm2 peptides containing phosphoserine 395. FLAG-Wip1 proteins were purified from 293HEK cells overexpressing
FLAG-Wip1 by affinity columns and incubated with an Mdm2 phosphoserine 395 peptide. A known Wip1 target phosphopeptide (pT180) from
p38 MAP kinase was utilized as a positive control. Free phosphate released by dephosphorylation was bound by molybdate and measured by
O.D. absorbance at 562 nm as previously described (Lu et al., 2004). Wip1 activity is magnesium dependent and is insensitive to the PP2A inhibitor
okadaic acid (OA). Error bars correspond to standard deviation of the mean.
(D) Wip1 dephosphorylates intact Mdm2 protein. Intact Mdm2 proteins were immunopurified from U2OS cells treated with IR and incubated with in-
dicated amounts of purifiedWip1. Dephosphorylation of Mdm2wasmeasured by immunoblotting with anMdm2 antibody (2A10) that only recognizes
unphosphorylated Mdm2 at serine 395.346 Cancer Cell 12, 342–354, October 2007 ª2007 Elsevier Inc.
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Regulation of the p53-Mdm2 Regulatory Loop by Wip1Wip1 with an Mdm2-derived phosphoserine 395 peptide
(Figure 3C) or intact immunopurified Mdm2 (Figure 3D).
The Mdm2 phosphopeptide was dephosphorylated by
Wip1 in a dose-dependent manner at serine 395, a site
that is phosphorylated by the ATM kinase (Maya et al.,
2001) (Figure 3C). This Wip1 activity was magnesium de-
pendent and okadaic acid insensitive, consistent with the
knownproperties ofWip1, a type 2Cphosphatase (Fiscella
et al., 1997) (Figures 3C and 3D). A monoclonal antibody
(2A10) that recognizes a nonphosphorylated serine 395
epitope of Mdm2 (Maya et al., 2001) was used to analyze
the phosphorylation status of Mdm2 in vitro with purified
Wip1 or in vivo in cells with overexpression or knockdown
of Wip1 (Figures 2D and 2E). Phosphorylation of Mdm2 at
serine 395 was inhibited by Wip1 in vitro or by Wip1 over-
expression in vivo and was enhanced by Wip1 siRNA
transfection following IR treatment of cells in vivo (Fig-
ure 3E). Three other serine/threonine protein phospha-
tases were tested in in vitro phosphatase assays with the
Mdm2 serine 395 phosphopeptide, including PP2A, which
has been shown to dephosphorylate Mdm2 at threonine
216 (Okamoto et al., 2002). Thesephosphatases (including
the closely relatedPP2Ca, which can augment p53 activity
[Ofek et al., 2003]) showed no appreciable enzyme activity
on the Mdm2 serine 395 phosphopeptide (Figure 3F).
Wip1 Enhances p53-Mdm2 Interaction
and Mdm2 Stability
Phosphorylation on p53 (ser15, thr18, ser20) and Mdm2
(ser395) inhibits the p53-Mdm2 interaction, suggesting
that Wip1 may facilitate this interaction through reduction
of phosphorylation (Bode and Dong, 2004; Moll and Pet-
renko, 2003). Indeed, Wip1 overexpression enhanced
the p53-Mdm2 interaction in IR-treated, p53-transfected
p53 null Saos-2 cells, leading to a reduced steady-state
level of p53 (and p53 serine 15 phosphorylation) after IR
treatment (Figure 4).
To assess Wip1 effects on Mdm2 protein levels, we ex-
amined p53 null Saos-2 cells and p53-containing HEK293
and U2OS cells transfected with Wip1 expression con-
structs or empty vectors. Wip1 attenuated the IR-associ-
ated decrease in Mdm2 levels in all three cell types (Fig-
ure 5A). We measured the half-life of wild-type and
phosphorylationmutantMdm2proteins inp53/Mdm2/
MEFs that simplify the analysis of transfected Mdm2 by
eliminating endogenous Mdm2. As measured by pulse-
chase analysis, the mean half-life of wild-type Mdm2 after
IR treatment was about 21 min, which extended to 38 min
in the presence of overexpressed Wip1 (Figure 5B). An
Mdm2mutation at Ser395 (S395A) thatmimics a nonphos-
phorylated form of Mdm2 resulted in enhanced Mdm2
stability, which was not significantly increased in the pres-Caence of Wip1 overexpression (Figure 5B). This suggests
that the primary effect of Wip1 on Mdm2 stability is medi-
ated by its dephosphorylation of serine 395. This is con-
firmed by theMdm2 S395Dmutant, whichmimics a phos-
phorylated form of Mdm2, since the mutant had a much
shorter half-life of about 8 min that was not significantly
affected by Wip1 overexpression (Figure 5B).
Since ATM phosphorylates Mdm2 at serine 395 (Maya
et al., 2001), we tested whether Wip1 effects on Mdm2
stability are ATM dependent. An ATM-deficient human
cell line (GM09607) was used to determine whether in-
creased levels of Wip1 promote Mdm2 accumulation in
the absence of functional ATM signaling.Mdm2 remained
relatively stable in IR-treated A-T cells regardless of Wip1
levels (Figure 5C). When ATM was reintroduced into
these cells, Mdm2 became more unstable following IR
treatment. Addition of Wip1 helped to stabilize Mdm2 in
the ATM-containing cells (Figure 5C), again indicating that
Wip1 stabilizes Mdm2 by reversing the destabilizing ef-
fects of ATM phosphorylation. To confirm that the effects
of Wip1 on p53 stability are largely Mdm2 dependent, we
transfected p53/Mdm2/ MEFs with exogenous p53
expression vectors with or without Wip1 expression con-
structs. Overexpression of Wip1 had no detectable effect
on p53 accumulation in the p53/Mdm2/ MEFs with
or without IR (Figure 5D). In contrast, introduction of Wip1
into wild-type MEFs inhibited p53 accumulation.
Wip1 May Augment Mdm2 Stability
by Suppressing Mdm2 Self-Interaction
and Autoubiquitination and by Enhancing
Mdm2-HAUSP Interactions
Mdm2 stability is regulated by autoubiquitination follow-
ing self-interaction of Mdm2 monomers (Meek and
Figure 4. Wip1 Enhances the p53-Mdm2 Interaction
Saos-2 cells were transfected with p53 expression vector DNA and
control DNA or Wip1 expression vector DNA. Twenty-four hours after
transfection, cells were treated with 5 Gy IR, harvested, and lysed at
indicated times. The p53-Mdm2 interaction was analyzed by immuno-
precipitation-western blotting as indicated.(E) Wip1 dephosphorylates Mdm2 in cells. U2OS cells were transfected with control DNA, Wip1 or phosphatase-dead Wip1 expression vector DNA,
or Wip1 siRNA-1, treated with 5 Gy IR, harvested 4 hr later, and immunoblotted with serine 395 phosphorylation-sensitive Mdm2 antibody 2A10
(top panel) or phosphorylation-insensitive Mdm2 antibodies 4B2 and 2A9 (middle panel).
(F) Wip1, but not other serine/threonine phosphatases, dephosphorylates Mdm2 at serine 395. Wip1, PP1, PP2A, and PP2Ca protein phosphatases
(PP) were incubated with their specific positive control phosphopeptides, or Mdm2 serine 395 phosphopeptide, or no peptide. The phosphatase ac-
tivity was measured as in (C). Error bars in (C) and (F) show the standard deviations of mean values.ncer Cell 12, 342–354, October 2007 ª2007 Elsevier Inc. 347
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Regulation of the p53-Mdm2 Regulatory Loop by Wip1Figure 5. Wip1 Stabilizes Mdm2 in an ATM-Dependent Manner
(A) Mdm2 levels are enhanced by overexpression of Wip1 in either p53 null or p53-expressing cells. Saos-2, 293HEK, and U2OS cells were trans-
fected with control DNA or Wip1 expression vector DNA. Twenty-four hours after transfection, cells were treated with 5 Gy IR, harvested and immu-
noblotted.
(B) Mdm2 is stabilized by Wip1. p53/Mdm2/ MEFs were transfected with wild-type Mdm2 or serine 395 mutant Mdm2 expression vector DNA
together with Wip1 expression vector DNA or control DNA. Twenty-four hours after transfection, cells were treated with 5 Gy IR. Cells were pulse
labeled with 35S-L-methionine and 35S-L-cysteine for 1 hr, harvested at the indicated time points after labeling, and cell lysates were immunoprecip-
itated with Mdm2 antibodies. The levels of Mdm2 at each time point were quantitated by phosphorimager for Mdm2 bands on SDS-PAGE gels, and
Mdm2 half-life was calculated (from two separate experiments) for the graph in the upper panel. Error bars correspond to standard deviation of the
mean.
(C) Wip1 stabilizes Mdm2 only in the presence of ATM. A-T cells (GM09607) were transfected with control DNA or Wip1 expression vector DNA, to-
gether with ATM expression vector DNA or control DNA. Twenty-four hours after transfection, cells were treated with 5 Gy IR, harvested, and immu-
noblotted as indicated.
(D) The accumulation of p53 is regulated by Wip1 primarily through Mdm2. Wild-type or p53/Mdm2/ MEFs were transfected with V5 epitope-
tagged Wip1 expression vector DNA or control DNA, together with p53 expression vector DNA. Twenty-four hours after transfection, cells were
treated with or without 5 Gy IR, and lysed 2 hr after irradiation and immunoblotted as indicated.Knippschild, 2003). We tested whether Wip1 regulates
Mdm2 stability by modulating Mdm2 self-interaction and
ubiquitination. To quantitate self-interaction of Mdm2,
expression vectors encoding HA- and FLAG-tagged
Mdm2 were cotransfected into HEK293 cells that induci-
bly express Wip1 in the presence of doxycycline. In-
creased Wip1 expression reduced the interaction be-
tween HA-Mdm2 and FLAG-Mdm2 before and after IR
treatment (Figure 6A). We then examined the effects of al-348 Cancer Cell 12, 342–354, October 2007 ª2007 Elsevier Inc.tered Wip1 levels on Mdm2 ubiquitination. Overexpres-
sion of Wip1 loweredMdm2 ubiquitination while reduction
of Wip1 levels through Wip1 siRNA transfection enhanced
Mdm2 ubiquitination compared to empty vector-trans-
fected control cells (Figure 6B). Thus, Wip1 promotes
Mdm2 stabilization through inhibition of Mdm2 autoubi-
quitination.
To assess the effects of Wip1 on Mdm2 deubiquitina-
tion, we examined binding of Mdm2 to HAUSP in U2OS
Cancer Cell
Regulation of the p53-Mdm2 Regulatory Loop by Wip1Figure 6. Wip1 Inhibits Ubiquitination of Mdm2
(A) Wip1 diminishes Mdm2 self-interaction. 293HEK cells that inducibly express Wip1 in the presence of doxycycline were transfected with equal
amounts of HA-Mdm2 and FLAG-Mdm2 expression vector DNA, treated with or without 5 Gy IR, and harvested 2 hr later. The Mdm2 self-interaction
was analyzed by immunoprecipitation and immunoblotting as indicated.
(B) Ubiquitination of Mdm2 is inhibited byWip1. The same 293HEK cells as above were transfectedwith HA-ubiquitin expression vector, together with
control DNA, or Wip1 expression vector DNA or Wip1 siRNA-1. Transfected cells were treated with or without 5 Gy IR and with protease inhibitor
MG132, and harvested 2 hr after IR. Cell lysates were immunoprecipitated with anti-HA antibody and immunoblotted by anti-Mdm2 antibody.
(C) Wip1 enhances the HAUSP-Mdm2 interaction. U2OS cells were transfected with or without Wip1 expression vector DNA, treated with IR, har-
vested, and immunoblotted as indicated.cells. HAUSP enhancesMdm2 stability by removing ubiq-
uitin moieties from Mdm2 (Li et al., 2004; Meulmeester
et al., 2005). While the levels of HAUSP remained con-
stant before and after ionizing radiation, the relative
amounts of Mdm2 bound to HAUSP were increased by
overexpressedWip1 (Figure 6C). This result suggests that
Wip1 enhances binding of HAUSP to Mdm2 and contrib-
utes to Mdm2 stability by facilitating its deubiquitination.
ATM-Independent Effects of Wip1
on Mdm2 Stability
In Figure 5C, when ATM-deficient human A-T cells were
treated with ionizing radiation, alteration of Wip1 levels
had little effect on apparent Mdm2 levels. When ATM
was restored in the A-T cells, increased Wip1 again stabi-
lized Mdm2. Such results suggested that Wip1 effects on
Mdm2 stability were largely ATM dependent. To deter-
mine whetherWip1 is solely ATMdependent or can exhibit
ATM independence, we assessed Wip1 effects on Mdm2
stability in the absence of ATM in two separate contexts.
First, we examined the effects of increased Wip1 levels
onMdm2 stability in UV-irradiated A-T cells. UV irradiation
primarily activates the ATR pathway rather than ATM, and
we hypothesized that ATR phosphorylation of Mdm2 ser-Cine 395might compensate for the absence of ATM. In fact,
overexpression of Wip1 did increase Mdm2 stability after
UV irradiation of A-T cells (Figure 7A). In addition, phos-
phorylation of Mdm2 serine 395 was lower in the UV irra-
diated A-T cells with extra Wip1, as measured by the
2A10 serine 395 epitope-specific antibody, suggesting
that ATR might be phosphorylating this site and that
Wip1 can suppress this phosphorylation even in the ab-
sence of ATM.
A second approach to assess ATM independence of
Wip1 was performed by examining Mdm2 stability in
mouse tissues lacking ATM in the presence and absence
ofWip1.WecrossedATM-deficientmice toWip1-deficient
mice and obtained ATM/Wip1/ F2 offspring after two
generations of crosses. ATM+/+Wip1+/+, ATM+/+Wip1/,
ATM/ Wip1+/+, and ATM/ Wip1/ mice were then
irradiated with 8 Gy ionizing radiation, and tissues were
harvested 16 hr later. Protein lysates from spleens were
western blot probed with antibodies to p53 protein, p53
serine 18 (the ATM/ATR phosphorylated mouse p53 site
equivalent to serine 15 on human p53), andMdm2 protein.
IrradiatedWip1/mice exhibited increased levels of p53
protein and p53 serine 18 phosphorylation compared to
wild-type mice (Figure 7B, lanes 5–8). Moreover, Mdm2ancer Cell 12, 342–354, October 2007 ª2007 Elsevier Inc. 349
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mice compared to wild-type mice. In the absence of ATM
(Figure 7B, lanes 9 and 10), levels of p53 protein and serine
18 phosphorylation were decreased and Mdm2 levels in-
creased. However, when both ATM andWip1 were absent
(Figure 7B, lanes 11and12), p53 levelswere increased and
Mdm2 levels were decreased relative to ATM-deficient
mice. This result is consistent with an ATM-independent
role of Wip1 in enhancement of Mdm2 stability and sup-
pression of p53 stability.
Figure 7. ATM-Independent Effects of Wip1 onMdm2 Protein
Levels
(A) Wip increases Mdm2 protein levels in UV-treated ATM-deficient
cells. GM09607 A-T cells were transfected with empty vector or
Wip1 expression vector. Twenty-four hours after transfection, the
GM09607 cells were UV irradiated (60 J/m2). Cell lysates were har-
vested at the indicated times post-V treatment, and western blots
were probed with the indicated antibodies. The Mdm2 2A10 antibody
is specific for the nonphosphorylated S395 form of Mdm2. The lower
graph shows the densitometric quantitation of relative unphosphory-
lated Mdm2 in empty vector or Wip1 vector-transfected cells.
(B) Absence of Wip1 in ATM-deficient mice suppresses Mdm2 protein
levels after ionizing radiation treatment. Adult (8–10 weeks) wild-type
(ATM+/+ Wip1+/+) mice, Wip1 null (ATM+/+ Wip1/) mice, ATM null
(ATM/Wip1+/+) mice, and ATM/Wip1 double null (ATM/Wip1/)
mice were treated with 8 Gy ionizing radiation and euthanized 16 hr
later. Spleen protein lysates were prepared and western blot probed
with the indicated antibodies. Two animals of each ATM/Wip1 geno-
type were irradiated, and Wip1/ mice consistently show reduced
Mdm2 protein levels compared to their Wip1+/+ counterparts in the
presence or absence of ATM. Shown at the left are spleen lysates
from nonirradiated mice, indicating little activation of p53 or Mdm2.350 Cancer Cell 12, 342–354, October 2007 ª2007 Elsevier IncDISCUSSION
The p53 protein is a key integrator of the DNA damage re-
sponse initiated by sensor kinases such as ATM and ATR
(Shiloh, 2003). Following DNA damage, ATM and ATR
phosphorylate p53 either directly or indirectly through in-
termediates such as Chk1 and Chk2 kinases (Toledo and
Wahl, 2006). Phosphorylation of p53 near its N terminus
is associated with activation of p53 in part through stabili-
zation. In conjunction with p53 phosphorylation, damage-
activated ATM also phosphorylates serine 395 on the E3
ubiquitin ligase Mdm2 (Maya et al., 2001). This particular
phosphorylation facilitates Mdm2 proteasomal degrada-
tion and reduces overall Mdm2 protein levels (Maya et al.,
2001; Stommel and Wahl, 2005). Thus, not only is less
Mdm2 available, but phosphorylation of p53 in the p53-
Mdm2bindingdomain likely preventsp53andMdm2 inter-
action (Bode and Dong, 2004). Since Mdm2 binding to
p53promotes p53 ubiquitination and degradation, preven-
tion of this binding is a major factor in stabilizing p53.
Stabilized and activated p53 transactivates a large bat-
tery of genes that canmediate DNA repair or arrest the cell
at multiple stages of the cell cycle (if apoptosis programs
are not engaged) (Figure 8). Assuming that p53 success-
fully facilitates cell cycle arrest and DNA repair, a mecha-
nism to return the cell to a predamage state is required.
Critical to returning the repaired cell to a homeostatic state
is the reduction of p53 levels. Central to this p53 homeo-
static response is the accumulation of Mdm2 following
transactivation by p53. Eventually, accumulated Mdm2
may bind to p53 and promote its degradation. This has
been the central paradigm of the p53-Mdm2 negative
feedback regulatory loop. However, this simple autoregu-
latory loop does not take into account the possibility that
p53 and Mdm2 may remain phosphorylated for some
time following DNA damage. One way to expedite p53
degradation after successful DNA repair would rely on de-
phosphorylation of those sites on p53 and Mdm2 that
inhibit p53-Mdm2 interactions.
The findings reported here indicate that the serine/
threonine phosphatase Wip1 plays an integral role in the
p53-Mdm2 negative feedback regulatory loop. The effects
of Wip1 on Mdm2 are multiple and include (1) dephos-
phorylation of Mdm2 at serine 395, (2) stabilization of
Mdm2 through decreasedMdm2 self-interaction and self-
ubiquitination, (3) stabilization of Mdm2 through facilita-
tion of HAUSP binding and Mdm2 deubiquitination, (4)
facilitation of Mdm2 binding to p53, and (5) stimulation of
Mdm2-mediated p53 ubiquitination and proteolytic deg-
radation (Figure 8). By dephosphorylating Mdm2 at serine
395, Wip1 reverses the effects of the ATM and ATR ki-
nases that enhance p53 stability and mediate the damage
response. Consistent with this scenario is the fact that, like
Mdm2,Wip1 is a p53 transcriptional target. The kinetics of
p53-mediated Wip1 induction are somewhat delayed
compared to that of p21 (compare Figure 1A and Fig-
ure 1C). Such a delay in Wip1 expression would allow
p53-induced cell cycle arrest and DNA repair to proceed
without premature interference..
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a molecular gatekeeper that allowsMdm2 to bindmore ef-
ficiently to p53. This promotes p53 ubiquitination and deg-
radation. Without Wip1, the p53 damage response is likely
to be enhanced and extendeddue in part to inefficient p53-
Mdm2 binding. This is seen in Figure 1, where Wip1 siRNA
treatment or targeted deletion of Wip1 in cells results in
increased p53 protein levels and activation of p53 target
genes following radiation compared to cells with normal
Wip1 activity. Moreover, in Figure 7, we show that tissues
of Wip1 null mice treated with ionizing radiation exhibit in-
creased p53 stabilization and p53 serine 18 phosphoryla-
tion in comparison to wild-type mice. This is correlated
with enhanced cancer resistance observed in the Wip1-
deficient animals (Nannenga et al., 2006).
Is dephosphorylation of Mdm2 at serine 395 the primary
mechanism by which Wip1 enhances stability of Mdm2?
While we believe this is the case, an alternative possibility
is that Wip1 dephosphorylation of ATM at serine 1981, as
recently demonstrated (Shreeram et al., 2006), will have
a similar effect in inhibiting ATM kinase function and leav-
ing Mdm2 unphosphorylated at serine 395. If this latter
scenario is dominant, Wip1 effects on Mdm2 stability
should be ATM dependent. In the absence of ATM, in-
creasedWip1 would have little or no effect on the unphos-
phorylated serine 395, and Mdm2 would be more stable
with or without Wip1. When ionizing radiation, which rap-
idly activatesATM, isapplied toATM-deficient cells,Mdm2
stability is in fact Wip1 independent (Figure 5C). However,
experiments presented in Figure 7Ashowed that, in the ab-
sence of ATM, ultraviolet radiation, which primarily acti-
vates ATR, results in Wip1-dependent Mdm2 stability.
Moreover, experiments in Figure 7B show ionizing radia-
tion applied to ATM null mice produces Wip1-dependent
Mdm2 alterations in stability in vivo, indicating that Wip1
Figure 8. Wip1 Plays Multiple Roles in the p53-Mdm2 Autore-
gulatory Loop
At left, early after DNA damage p53 levels are stabilized as a result of
p53 and Mdm2 phosphorylation by ATM. Phosphorylation of Mdm2
destabilizes it and results in self-ubiquitination and degradation. Stabi-
lized p53 transactivates a number of genes including p21,Mdm2, and
Wip1. At right, at later time points after damage, Mdm2 and Wip1 pro-
tein levels increase, and Wip1 dephosphorylates p53 and Mdm2, sta-
bilizing Mdm2 in part through interactions with the HAUSP deubiquiti-
nase. Dephosphorylated p53 and Mdm2 more readily bind, initiating
the ubiquitination-mediated proteolysis of p53. This reduces p53 pro-
tein levels and returns the cell to a prestress-like state.Cais ATM independent in multiple contexts. These latter ex-
periments likely entailed the activation of other sensor ki-
nases such asATRandDNA-PKcs,which can compensate
for ATM absence by phosphorylating many ATM targets.
However, even in the presence of activated ATM, it seems
likely that Wip1 dephosphorylation of both ATM serine
1981 andMdm2 serine 395 contributes toMdm2 stabiliza-
tion. We conclude that a major component of Wip1 effects
onMdm2 stability is a result of direct dephosphorylation of
Mdm2 at serine 395, reversing the effects of phosphoryla-
tion at this site by ATM and other kinases such as ATR.
In addition to the effects of Wip1 on p53 activity via
Mdm2,Wip1may suppress p53 activities by other mecha-
nisms. Wip1 dephosphorylates and reduces the activities
of the upstream p53 targeting kinases p38 MAP kinase
(phosphorylates p53 serines 33 and 46), ATM (phosphory-
lates p53 serine 15), and Chk1 and Chk2 (p53 serine 20
phosphorylation) (Fujimoto et al., 2006; Lu et al., 2005;
Oliva-Trastoy et al., 2006;Shreeramet al., 2006; Takekawa
et al., 2000; Yoda et al., 2006). Dephosphorylation at each
of these sites is likely to reduce p53 activity. For example,
phosphorylation of p53 serines 33 and 46 by p38 MAP ki-
nase promotes p53 apoptotic function (Sanchez-Prieto
et al., 2000). That serine 15 phosphorylation by ATM plays
a significant role in p53 function is underlined by the finding
that mutation of serine 18 to a nonphosphorylatable ala-
nine results in mice with decreased damage-induced apo-
ptotic function and an accelerated rate of tumor formation
(Sluss et al., 2004; S.N.J., unpublished data). In addition to
inhibiting ATM phosphorylation of p53 serine 15, Wip1 de-
phosphorylates p53 at this site (Lu et al., 2005).
The ability of Wip1 to suppress p53 activity through dif-
ferent mechanisms makes it an obvious oncogene candi-
date, analogous in someways toMdm2, which appears to
be oncogenic largely due to inhibition of p53 (Bond et al.,
2005; Momand et al., 1998). Indeed, Wip1 can cooperate
with Ras and other oncogenes to transform rodent pri-
mary fibroblasts (Bulavin et al., 2002; Li et al., 2002; Nan-
nenga et al., 2006). In contrast, Wip1 null MEFs are resis-
tant to oncogene-induced transformation (Bulavin et al.,
2004). Moreover, overexpression of Wip1 in mouse mam-
mary gland accelerates mammary tumorigenesis initiated
by the ErbB2 oncogene (Demidov et al., 2007), while Wip1
null mice are resistant to spontaneous and oncogene-
induced cancers (Bulavin et al., 2004; Nannenga et al.,
2006). Finally, some human cancer types exhibit amplifi-
cation and overexpression of Wip1 (Bulavin et al., 2002;
Hirasawa et al., 2003; Li et al., 2002; Mendrzyk et al.,
2005; Saito-Ohara et al., 2003). That Wip1 is oncogenic
in part through its ability to suppress p53 is suggested
by the virtual absence of p53 mutations in breast tumors
with amplified Wip1 (Bulavin et al., 2002). Thus, Wip1 is
unusual in being a serine/threonine phosphatase that
behaves as an oncogene.
In summary, we have demonstrated here that Wip1
plays an important role in the p53-Mdm2 autoregulatory
loop. It is upregulated in a p53-dependent manner follow-
ing DNA damage and it acts to stabilize Mdm2 by dephos-
phorylating it at serine 395, thus reversing the destabilizingncer Cell 12, 342–354, October 2007 ª2007 Elsevier Inc. 351
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turn, dephosphorylated Mdm2 is stabilized and more ca-
pable of binding to p53 (also dephosphorylated by Wip1)
and mediating its ubiquitination and proteasomal degra-
dation. The above scenario provides further mechanistic
insights into Wip1 oncogenic function that supplements
previous studies implicating Wip1 in suppression of p38
MAP kinase signaling, ATM/ATR signaling, p16INK4A func-
tion, cell cycle checkpoints, and DNA repair (Bulavin et al.,
2004; Demidov et al., 2007; Lu et al., 2004, 2005). Thus, in-
terruption of Wip1 function in cancers could be an effec-
tive therapeutic approach that merits further study.
EXPERIMENTAL PROCEDURES
Cell Lines and Cell Culture
U2OS (p53 wild-type) and Saos-2 (p53 null) cell lines are human oste-
osarcoma lines that were obtained from the American Type Culture
Collection (ATCC). Primary Wip1+/+, Wip1/, and p53/Mdm2/
MEFs were harvested and cultured as previously described (Choi
et al., 2002; Jones et al., 1996). The A-T cell line GM09607 was ob-
tained from Coriell Cell Repositories. 293 HEK Tet-on cells were ob-
tained from BD Biosciences (BD Biosciences, catalog #630903). To
obtain cells stably expressing Wip1, FLAG-tagged Wip1 cDNA was in-
serted into the BamH1 site in pRevTRE vector (BD Biosciences, cata-
log #631002). Together with retroviral packaging plasmids pVSVG and
pHit60 (provided by R. Sutton), pRexTRE-Wip1 was transfected into
293T cells to generate retroviral vectors containing FLAG-Wip1. 293
HEK Tet-on cells were infected with the above retrovirus, then
screened with 400 mg/ml hygromycin. Twelve hygromycin-resistant
positive colonies were isolated, amplified, and checked for inducible
expression of Flag-Wip1 protein following addition of 5.0 mg/ml doxy-
cycline (BD Biosciences, catalog #631311) individually. Clonal lines
with high levels of inducible Wip1 expression and low basal levels of
FLAG-Wip1 were used for the experiments described in this paper.
Mice and Mouse Embryo Fibroblasts
ATM-deficient mice were a generous gift from Dr. Ben Zhu and have
been previously described (Sekiguchi et al., 2001). The ATM-deficient
mice were crossed to Wip1 mice previously generated by our labora-
tory (Choi et al., 2002), and ATM/ Wip1/ F2 offspring were ob-
tained. For the experiments in Figure 7B, two 8- to 10-week-old
male mice of each ATM/Wip1 genotype (ATM+/+ Wip1+/+, ATM+/+
Wip1/, ATM/ Wip1+/+, and ATM/ Wip1/) were irradiated
with 8 Gy ionizing radiation and were euthanized 16 hr later. For mouse
embryo fibroblast studies using Wip1/ MEFs, Wip1+/ mice were
crossed and MEFs prepared as described previously (Choi et al.,
2002). p53/Mdm2/ MEFs were prepared in a similar manner
from p53/Mdm2/ parental crosses (Jones et al., 1996). All exper-
iments utilizing mice were performed in accordance with relevant
regulatory standards regarding animal research and were approved
by the Baylor College of Medicine Institutional Animal Care and Use
Committee.
Plasmid Constructs and siRNAs
Wild-type Wip1 plasmids expressing mouse and human Wip1 used in
these experiments have been previously described (Lu et al., 2004).
The phosphatase-dead Wip1 point mutant D314A is catalytically inac-
tive and was obtained from Dr. Y. Minami (Yoda et al., 2006). The p21-
luciferase construct was obtained from Dr. G. Lozano. The vectors ex-
pressing wild-type Mdm2, Mdm2 (S395A and S395D) were previously
described (Maya et al., 2001). The sequences of the Wip1 siRNAs are
GGCUUUCUCGCUUGUCACC (siRNA-1) and UUGGCCUUGUGCC
UACUAA (siRNA-2). Control scrambled siRNA was purchased from
Dharmacon (catalog #D-001210-01-05).352 Cancer Cell 12, 342–354, October 2007 ª2007 Elsevier Inc.Cell Transfection with Plasmid DNA or siRNA
Cells were transfected with plasmid DNA by Lipofectamine and Plus
reagents (for transformed cell lines, Invitrogen, catalog #18324-012
and #11514-015) or Lipofectamine 2000 reagent (for MEFs, Invitrogen,
catalog #11668-019). Oligofectamine reagents (Invitrogen, catalog
#12252-011) were utilized to transfect cells with siRNAs. Transfection
experiments were performed following the instruction manuals pro-
vided with reagents.
Luciferase Assays
U2OS cells were cotransfected with p21-Luciferease DNA, Renilla lu-
ciferase DNA, and Wip1 expression vector DNA or Wip1 siRNA. Cells
were harvested at various time points and lysed. Luciferase activity
was measured using a Turner TD-20e luminometer and normalized
to renilla luciferase according to the instructions provided with the
dual-luciferase assay kit (Promega).
Gene Expression Microarray Analysis
RNA was extracted from 60 mm dishes of irradiated or nonirradiated
Wip1+/+ or Wip1/ MEFs 4 hr after 5 Gy of radiation with RNeasy
Mini Kit (QIAGEN). Following quality check of theRNA,microarray anal-
ysis was performed at Baylor Microarray Core Facility (http://www.
bcm.edu/mcfweb/) with Affymetrix Mouse Genome 430 2.0 Chips.
Microarray data were analyzed with Genesifter software (http://www.
genesifter.net/). The raw data for the microarray analyses have been
deposited in the GEO public database (accession #GSE8704).
Western Blot and Immunoprecipitation-Western
Blot Analysis
Immunoprecipitations, western blot analysis, and immunoprecipita-
tion-western blot analyses were performed by standard methods
and have been described previously (Lu et al., 2005). Antibodies were
obtained from commercial sources. These are listed in the next sec-
tion. Note that 4B2 and 2A9 antibodies (Calbiochem) were mixed
and used to immunoprecipitate or immunoblot total Mdm2, and 2A10
antibody was only used to detect nonphosphorylated Mdm2.
Antibodies and Purified Proteins
Anti-p53 (#9292 and #2524) and anti-p53(p15S) (#9286) were pur-
chased from Cell Signaling Technology; anti-actin (#1616), anti-ATM
(#23921), anti-ubiquitin (#8017), HRP-anti-goat IgG (#2020), HRP-
anti-rabbit IgG (#2302), and HRP-anti-mouse IgG (#2302) were pur-
chased from Santa Cruz; anti-HAUSP (#A300-033A) and anti-HA
(A190-108A) were purchased from Bethyl Laboratories; anti-FLAG
(#V8012) and anti-V5 (#P2963) were purchased from Sigma-Aldrich;
anti-Wip1 (#2380-MC-100) was purchased from Trevigen; anti-
Mdm2 (2A10, 4B2, and 2A9), purified PP1 (#539493), and PP2Ca
(#539569) were obtained from Calbiochem. PP2A (#14-165) was ob-
tained from Upstate. For the Mdm2 protein blots on Wip1/ MEFs
in Figure 1C, the Mdm2 antibodies used were from Santa Cruz
(Mdm2 C-18 and Mdm2 K-20 mixed together 1:1). For the mouse
spleen western blots in Figure 7B, Mdm2 antibodies C-18, K-20, and
H221 from Santa Cruz were mixed in 1:1:1 ratios. The p53 antibody
in this experiment was p53 AB1 and AB3 from Calbiochem mixed in
a 1:1 ratio. The anti-p53(pS18) antibody used was catalog number
9284 from Cell Signaling Technology.
Protein Stability Measurement
P53/Mdm2/ MEFs were transfected with expression vector DNA
containing wild-type Mdm2, Mdm2 (S395A), or Mdm2 (S395D), with
or withoutWip1 expression vector DNA. Twenty-four hours after trans-
fection, cellswere treatedwith 5Gy IR.Cellswerepulse labeled iname-
dium containing 35S-L-methionine and 35S-L-cysteine for 1 hr and then
changed to the regular culture medium. Cells were harvested at the
indicated time points after labeling, and cell lysates were immunopre-
cipitated with Mdm2 antibodies. Mdm2 immunoprecipitates were run
in the SDS-PAGE. The levels of Mdm2 at each time point were quanti-
tated by phosphorimager for Mdm2 bands on SDS-PAGE gels.
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The in vitro phosphatase assays have been described previously (Lu
et al., 2004). Mdm2 phosphopeptide (Ac-ESEDYpSQPSTS-amide)
was custom synthesized by New England Peptide. Intact Mdm2 pro-
teins were immunopurified with anti-Mdm2 antibodies.
Ubiquitination Assays
Cells were treated with proteasome inhibitors MG101 (25 mM) and
MG132 (25 mM). Six hours after treatment, cells were harvested and
lysed in the lysis buffer (20 mM HEPES [pH 7.4], 240 mM NaCl, 0.1
mM EDTA, 0.5% Triton X-100 or 0.1% SDS, 1 mM PMSF, 1 mM
DTT, and Complete Mini protease inhibitor tablet from Roche). Ubiqui-
tinated p53 was immunoprecipitated with anti-p53 (#126, Santa Cruz)
and then was western blot analyzed with anti-ubiquitin antibody
(#P4D1, Santa Cruz). Ubiquitinated Mdm2 was immunoprecipitated
with anti-HA antibody (against HA-ubiquitin) and then western blot
analyzed with anti-Mdm2 (4B2 and 2A6 from Calbiochem) antibodies.
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